These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21488346)

  • 1. [Hepatocellular carcinoma].
    Kudo M
    Nihon Geka Gakkai Zasshi; 2011 Mar; 112(2):122-9. PubMed ID: 21488346
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
    Subramanian M; Singal AG; Yopp AC
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):e83-4. PubMed ID: 22813441
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S; Bouattour M; Raymond E
    Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma.
    Zhao Y; Yang M; Qi X; Han G; Fan D
    Hepatology; 2012 Aug; 56(2):790-1. PubMed ID: 22307917
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib use in hepatocellular carcinoma: more questions than answers.
    Abou-Alfa GK
    Hepatology; 2014 Jul; 60(1):15-8. PubMed ID: 24493250
    [No Abstract]   [Full Text] [Related]  

  • 9. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.
    Bettinger D; Schultheiss M; Knüppel E; Thimme R; Blum HE; Spangenberg HC
    Hepatology; 2012 Aug; 56(2):789-90. PubMed ID: 22307848
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
    Printz C
    Cancer; 2009 Oct; 115(20):4646. PubMed ID: 19806596
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword.
    Kummar S
    Curr Probl Cancer; 2010; 34(2):130. PubMed ID: 20417352
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib in clinical practice: evidence-based use or abuse?
    Basso M; Basso M; Barone C
    Hepatology; 2012 Apr; 55(4):1305; author reply 1305-6. PubMed ID: 22189632
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
    Schraml C; Schwenzer NF; Martirosian P; Bitzer M; Lauer U; Claussen CD; Horger M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W301-7. PubMed ID: 19770299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
    Yu L; Dai Z; Zhou J; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):475-7. PubMed ID: 19567036
    [No Abstract]   [Full Text] [Related]  

  • 15. 'I am not going to live to regret that, am I?' A pseudo-hepatocellular carcinoma case.
    Abbass K; Markert RJ; Kaplon MK
    Liver Int; 2011 Oct; 31(9):1418. PubMed ID: 21752176
    [No Abstract]   [Full Text] [Related]  

  • 16. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
    Novi M; Lauritano EC; Piscaglia AC; Barbaro B; Zocco MA; Pompili M; Gasbarrini A
    Am J Gastroenterol; 2009 Jul; 104(7):1852-4. PubMed ID: 19574982
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T; Tsuchiya K; Izumi N
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    Lencioni R; Chen XP; Dagher L; Venook AP
    Oncologist; 2010; 15 Suppl 4():42-52. PubMed ID: 21115580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS
    Clin Cancer Res; 2010 Jan; 16(2):390-7. PubMed ID: 20068087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.